1175. Acute vs. Subacute Community-acquired Meningitis: Analysis of 611 Adult patients
Session: Poster Abstract Session: Clinical Infectious Diseases: CNS Infection
Friday, October 28, 2016
Room: Poster Hall
Background: Community-acquired meningitis can be classified into acute and subacute presentations by the duration of illness of less or more than 5 days, respectively. There are currently no studies comparing the clinical features, management decisions, etiologies and outcomes between acute and subacute presentations.

Methods: A retrospective study of adults with community-acquired meningitis hospitalized in Houston, Texas between January 2005 and December 2009. An adverse clinical outcome was defined as a Glasgow Outcome Scale score of 4 or less.

Results: A total of 611 patients were identified, of which 458 (80%) were acute and 153 subacute (20%). The most common etiologies were unknown in 405 (66.3%), viral in 102 (16.7%), bacterial in 48 (7.9%) and fungal in 44 patients (7.2%). Patients with subacute meningitis were more likely to be immunosuppressed, had fungal etiologies, more hypoglycorrachia, higher rates of comorbidities, more abnormal neurological exams and adverse clinical outcomes (ACO) (p<0.05). Patients with an acute presentation were more likely to be treated empirically with intravenous antibiotics and had higher CSF pleocytosis and serum WBC counts (p<0.05). On logistic regression, age > 65 years, and altered mental status were predictive of an adverse clinical outcome in both acute and subacute meningitis; whereas fever and focal neurological deficits were also significant prognostic factors in acute meningitis. (P<0.05).

Conclusion: Acute and subacute meningitis differ in regards to clinical presentations, etiologies, management decisions, and outcomes. Subacute meningitis is associated with more severe disease and has worse clinical outcomes.

Tarek Sulaiman, MD, UT Health, Houston, TX, Lucrecia Salazar, MD, Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, TX and Rodrigo Hasbun, MD, MPH, Division of Infectious Diseases, University of Texas Health Science Center at Houston, Houston, TX

Disclosures:

T. Sulaiman, None

L. Salazar, None

R. Hasbun, None

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.